Hi Mateo,
Hope your well.
I'm not sure if you watched the recent MST financial webinar (very impressive in my view). But they are expecting ATH434 to be used in early stages of PD, as MSA and PD affect similar regions of the brain in early stages, and therefore to hard to disseminate. Given this, Dr Stamler had mentioned ATH434 will be utilised in the treatment of PD.
Just have to cross the finish line and get the final readout.
Good to look at the reference study by Wenning et al, page-9
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $570 | 149.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 13513113 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 130775819 | 29 |
View Market Depth
| Last trade - 15.46pm 27/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |